{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:federal-register-2024-21241:v1","objectPathId":"federal-register-2024-21241-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/federal-register-2024-21241/","json":"https://peptidescanner.com/evidence/v1/objects/federal-register-2024-21241-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/federal-register-2024-21241-v1.md"},"story":{"slug":"federal-register-2024-21241","version":1,"domain":"Regulatory","dateInSource":"2024-09-18","sourceCheckedAt":"2026-08-21","publishedAt":"2026-08-21","peptideSlugs":["ipamorelin"],"peptides":[{"slug":"ipamorelin","url":"https://peptidescanner.com/peptides/ipamorelin/"}]},"claims":[{"id":"headline","text":"Federal Register notice 2024-21241","sourceIds":["federal-register-2024-21241-bbe8399c5872"]},{"id":"summary","text":"The Federal Register published notice 2024-21241, attributed to FDA and its parent HHS department, on 2024-09-18. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List,” and PeptideScanner's exact reviewed identity mapping connects the document to Ipamorelin.","sourceIds":["federal-register-2024-21241-bbe8399c5872"]},{"id":"paragraph-1","text":"The Federal Register published notice 2024-21241, attributed to FDA and its parent HHS department, on 2024-09-18. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List,” and PeptideScanner's exact reviewed identity mapping connects the document to Ipamorelin.","sourceIds":["federal-register-2024-21241-bbe8399c5872"]},{"id":"paragraph-2","text":"This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use.","sourceIds":["federal-register-2024-21241-bbe8399c5872"]}],"sources":[{"id":"federal-register-2024-21241-bbe8399c5872","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List","url":"https://www.govinfo.gov/content/pkg/FR-2024-09-18/pdf/2024-21241.pdf"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"01abc5373552178e79eb44250a90e2b5b0a758757b156eb91c7e0fd7e3e67b9d","tierARecordSha256":"bbe8399c58724be74566403fb9abaee072e10fc67db57a4e85b604de458d7d70"},"integrity":{"algorithm":"sha256","contentSha256":"cd774ebfa05658d81b0688fcb6c78d4bf57878ec9be4c1909dcb02e06cc462c6"}}